Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) Is Currently -448.15% Below Its 52-Week High, But Upside Potential Is Still There.
In recent trading session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) saw 0.42 million shares changing hands at last check today with its beta currently measuring 2.91.